NACDS Submits Comments to FDA on Expanding Access to Nonprescription Drugs
Comments emphasize the importance of coordinated policy and operational alignment to support affordable and seamless patient access.
Comments emphasize the importance of coordinated policy and operational alignment to support affordable and seamless patient access.
Pharmacists ready to help Americans save more as FDA streamlines biosimilar approvals and advances interchangeability; NACDS urges Congress to finish its job on PBM reform.
NACDS also praises Congressional engagement to prevent disruptions of patients’ access to prescription drugs through no fault of dispensers.
This situation jeopardizes patients' access to prescription drugs, through no fault of dispensers.
This delay is an acknowledgement of a much needed delay – advocated by NACDS, along with supply chain and other pharmacy partners – to address technical and operational issues that had the potential to create supply chain disruptions and adversely impact patients’ access to needed medications.
Seventy-two percent who support track and trace, and 70% of those who have experienced a medicine or health product shortage, back an extension of the DSCSA’s final implementation date.
“Specifically, we request FDA use its authority under the law for dispensers to comply with the EDDS requirements no earlier than February 27, 2026.”
The National Association of Chain Drug Stores (NACDS)-backed move — which will greatly enhance patients’ access to hearing aids — comes out of a final rule issued by the Food and Drug Administration (FDA) in mid-August.
The importance of the issue is underscored given rising rates of COVID-19 fueled by Omicron subvariants.
NACDS today welcomed the announcement by the U.S. Food and Drug Administration (FDA) that it revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), “to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.”